#Obesity medicine
Chronic weight management as a clinical specialty.
Semaglutide and aspiration risk in surgery
New ultrasound data and case reports on semaglutide, retained gastric content and aspiration are reshaping the pre-surgery cessation question.
What is GEP44? A GLP-1/PYY explainer
GEP44 is an investigational peptide that pairs GLP-1 with peptide YY signalling to test whether weight loss can come with fewer GI side effects.
Retatrutide and gallbladder disease risk
Retatrutide is an investigational GLP-1, GIP and glucagon triple agonist. Here is what the trial and label data show about gallbladder risk.
Compounded tirzepatide with B6 explained
Compounded tirzepatide, including preparations with added vitamin B6, is not the licensed medicine. Here is what is documented and what is not.
How GLP-1 weight loss drugs really differ
Novo's CEO says patients want optionality. Here is what the approved labels and the single head-to-head trial say really separates these drugs.
GLP-1 gastroparesis symptoms and the gaps
A 2026 systematic review found only 12 published case reports of GLP-1 gastroparesis. Here is what they showed, and what they cannot tell you.
GLP-1 drugs at longevity clinics
Longevity and aesthetic clinics prescribe semaglutide and tirzepatide off-label. Here is what the labels cover, and where the ageing evidence stops.
Tirzepatide, blood pressure, cholesterol
A SURMOUNT post hoc analysis scores tirzepatide on all three targets at once. Between 32% and 38% of participants hit every one. Composites read differently.
Do GLP-1 drugs cause throat symptoms?
A 2026 Laryngoscope cohort ties GLP-1 drugs to cough, globus and voice change. Here is what an association study can and cannot show.
What Lilly's retatrutide lawsuits mean
Eli Lilly sued six US sellers of unapproved retatrutide on 12 August 2026. Here is what the cases mean if you bought a vial or are considering one.
Semaglutide and reward: what research shows
GLP-1 receptors sit inside the brain's dopamine reward circuit. Early trials suggest semaglutide may reduce craving well beyond food.
Surgery vs semaglutide for heart outcomes
A large real-world study compared semaglutide with bariatric surgery on heart outcomes in obesity. Here is what it found and what it cannot prove.